Epidermal growth factor receptor (EGFR) mutations occur in up to 50% of Asian patients with
non-small cell lung cancer (NSCLC). Treatment of advanced NSCLC patients with EGFR-tyrosine
kinase inhibitors (EGFR-TKI) confers a significant survival benefit. This study assessed the
efficacy and safety of chemotherapy with or without icotinib in patients undergoing resection
of stage IB to IIIA EGFR-mutated NSCLC.